To reconcile the efficacy of combining mTORC1 and TGM2 inhibition in tumor cells with mTORC1-hyperactive cells in vivo, we developed an MCF-7-luciferase-tagged xenograft tumor model. Here, TGM2 is linked to neoplasm.